A case report of successful long-term relapse control by protein-a immunoadsorption in an immunosuppressive-treated patient with end-stage renal disease due to wegener's granulomatosis

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 2, 2009, Pages 150-156

  Koch, Michael ^a,b   Kohnle, Matthias ^b   Trapp, Rudolf ^b  

^a Mettmann ^*  (Germany)

^b Center of Nephrology   (Germany)

Author keywords

End stage renal disease; Immunosuppressive therapy; Protein A immunoadsorption; Relapse; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN A;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; FRAILNESS; HEMODIALYSIS PATIENT; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MAINTENANCE THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; WEAKNESS; WEGENER GRANULOMATOSIS;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MYCOPHENOLIC ACID; PREDNISONE; REMISSION INDUCTION; RENAL DIALYSIS; STAPHYLOCOCCAL PROTEIN A; WEGENER GRANULOMATOSIS;

EID: 63349097634     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00670.x     Document Type: Article

References (17)

1. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004 117 : 39 50.
2. Wegener F. Über generalisierte, septische Gefässerkrankungen. Report of 3 cases. Verh Dtsch Ges Pathol 1936 29 : 202.
3. Belak M, Borberg H, Jimenez C, Oette K. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci 1994 15 : 419 22.
4. Koch M, Trapp R. Ethyl mercury poisoning during a protein A immunoadsorption treatment. Am J Kidney Dis 2006 47 : e31 4.
5. Riccieri V, Valesini G Treatment of Wegener's granulomatosis Reumatismo 2004 56 : 69 76.
6. Haubitz M. ANCA-associated vasculitis: diagnosis, clinical characteristics and treatment. Vasa 2007 36 : 81 9.
7. Pedersen RS, Aunsholt NA. Hemodialysis does not always protect against recurrence of Wegener's granulomatosis. Scand J Urol Nephrol 1990 24 : 223 5.
8. Kuross S, Davin T, Kjellstrand CM. Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. Clin Nephrol 1981 16 : 172 80.
9. Weidanz F, Day CJ, Hewins P, Savage CO, Harper L. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 2007 50 : 36 46.
10. Haubitz M, Koch KM, Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant 1998 13 : 1713 8.
11. Matic G, Michelsen A, Hofmann D et al. Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment. Ther Apher 2001 5 : 68 72.
12. Schneidewind J, Gliesche T, Sehland D et al. Protein A immunoadsorption al a new apheresis procedure for elimination of HLA antibodies Beitr Infusionsther Transfusionsmed 1994 32 : 360 5.
13. Antoniu SA. Treatment options for refractory Wegener's granulomatosis: a role for rituximab? Curr Opin Investig Drugs 2007 8 : 927 32.
14. Iwatani H, Uzu T, Kakihara M et al. A case of Wegener's granulomatosis with pulmonary bleeding successfully treated with double filtration plasmapheresis (DFPP). Clin Exp Nephrol 2004 8 : 369 74.
15. Lyu RK, Chen WH, Hsieh ST. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barre syndrome. Ther Apher 2002 6 : 163 6.
16. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995 101 : 2 7.
17. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000 93 : 433 9.